PTC THERAPEUTICS INC (PTCT) 46.25 +0.26 (+0.57%)
46.25 +0.26 (+0.57%)
US69366J2006 - Common Stock - After market: 46.25 0 (0%)
NICE recomenda reembolso para Translarna™
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de...
NICE recomienda el reembolso de Translarna™
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics Breaks Above 200-Day Moving Average - Bullish for PTCT
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan...
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan...
7 Nasdaq Stocks to Sell Before They Plunge in 2023
While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one.
Autoridade Reguladora Brasileira concede aprovação a Waylivra™ para Lipodistrofia Parcial Familiar
/PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou o Waylivra™...
La autoridad reguladora brasileña otorga su aprobación a Waylivra™ para tratar la lipodistrofia parcial familiar
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de...
Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...
Notable Two Hundred Day Moving Average Cross - PTCT
PTC Therapeutics is Now Oversold (PTCT)
Interesting PTCT Put And Call Options For June 2023
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the...
Notable Tuesday Option Activity: PTCT, ULTA, CRWD
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022...
Associação de pacientes brasileira recebe STRIVE(TM) Award 2022 da PTC Therapeutics para distrofia muscular de Duchenne
/PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anuncia que uma associação de pacientes brasileira é uma das quatro ganhadoras do programa global...